5.20Open5.20Pre Close0 Volume1 Open Interest10.00Strike Price0.00Turnover505.27%IV-31.41%PremiumDec 20, 2024Expiry Date12.16Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9472Delta0.0080Gamma1.77Leverage Ratio-0.1336Theta0.0012Rho1.67Eff Leverage0.0029Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet